Methods of Treating Giardiasis Using FDA-Approved Compounds

This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions.

IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)

Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment. 

Micro-Dose Calibrator for Pre-clinical Radiotracer Assays

Molecular imaging is a disease-specific targeting modality that promises much more accurate diagnoses of serious diseases such as cancer and infections. Agents are being continually developed with a view to clinical translation, with several such therapies requiring measurement of very small doses. Currently, there is no way of accurately measuring small amounts of radioactivity used in many pre-clinical tracer studies, as on-the-market commercial dose calibrators measure at too high a dose range, typically at 10-1000 µCi and higher.

Removal of Selected Proteins Using Light Energy: Photoimmunotherapy

Researchers at the NCI  Laboratory of Molecular Theranostics and the Molecular Imaging Program have developed a new method to modify, isolate and remove a single chemically-labeled molecule or a cluster of proteins associated with the chemically-labeled protein. The chemical label can be an antigen-antibody complex. This discovery is based on the mechanism of photo-immunotherapy (PIT).

89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods

This technology from the NCI Molecular Imaging Program relates to a Zirconium-89 (89Zr)-oxine complex for cell labeling, tracking of labeled cells by whole-body positron emission tomography/computed tomography (PET/CT) imaging, and associated methods. A long half-life of 89Zr (78.4 hours), high sensitivity of PET, and absence of background signal in the recipient enable tracking cells over a week using low levels of labeling radioactivity without causing cellular toxicity.

Video Monitoring and Analysis System for Vivarium Cage Racks

This invention pertains to a system for continuous observation of rodents in home-cage environments with the specific aim to facilitate the quantification of activity levels and behavioral patterns for mice housed in a commercial ventilated cage rack.  The home-cage in-rack provides daytime and nighttime monitoring with the stability and consistency of a home cage environment.

Henipavirus Vaccine

Henipaviruses are RNA viruses containing two high consequence human pathogens: Nipah virus (NiV) and Hendra virus (HeV). Both NiV and HeV infection in humans can result in severe respiratory disease and/or severe neurological manifestations, with mortality rates as high as 80%. There are currently no FDA-approved vaccines or therapeutics, and both NiV and HeV are considered dangerous emerging human pathogens with pandemic potential.

Novel Antiviral—Griffithsin Derived from Algae—for Prophylaxis or Treatment of Rabies Infection

Rabies virus (RABV) infection leads to fatal encephalitis—inflammation of the brain—if left untreated. Millions of people survive RABV infection each year due to timely administration of post-exposure treatment, however, nearly 60,000 people die from rabies each year according to the World Health Organization. Obstacles to timely treatment for RABV infection include the high cost and burdensome storage requirements (i.e., refrigeration) of current post-exposure treatments (i.e., rabies immunoglobulin (RIG)).

Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications

CDC and collaborating researchers have developed a new monoclonal antibody that recognizes canine IgG (likely IgG4 subclass). This anti-dog IgG reagent could be used to detect antibody reactions to a variety of antigens and has potential use in a wide variety of diagnostic or research applications.

Monoclonal Antibodies for Detection of Rabies Virus Antigen and Confirmatory Rabies Diagnosis

According to the World Health Organization (WHO), rabies causes greater than 59,000 deaths every year in over 150 countries as of 2017. A rapid and reliable diagnostic test for rabies is critical for prophylaxis considerations in humans bitten by animals as well as for basic surveillance and animal rabies control programs. The World Organization of Animal Health (OIE) and WHO Expert Committee on Rabies recently approved the direct rapid immunohistochemical test (DRIT) for rabies diagnostics.
Subscribe to Collaboration